Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jun;9(6):1374-6.
doi: 10.3748/wjg.v9.i6.1374.

Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma

Kuai-Le Zhao  1 , Yang Wang, Xue-Hui Shi
Affiliations

Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma

Kuai-Le Zhao et al. World J Gastroenterol. 2003 Jun.

Abstract

Aim: This retrospective study was designed to analyze the results and the failure patterns of late course accelerated hyperfractionated radiotherapy for clinical T(1-2)N(0)M(0) esophageal carcinoma.

Methods: From Aug. 1994 to Feb. 2001, 56 patients with clinical T(1-2) esophageal carcinoma received late course accelerated hyperfractionated radiotherapy in Cancer Hospital, Fudan University. All patients had been histologically proven to have squamous cell carcinoma (SCC) and were diagnosed to be T(1-2)N(0)M(0) by CT scan. All patients were treated with conventional fractionation (CF) irradiation during the first two-thirds course of the treatment to a dose of about 41.4Gy/23fx/4 to 5 weeks, Which was then followed by accelerated hyperfractionation irradiation using reduced fields, twice daily at 1.5Gy per fraction, to a dose about 27Gy/18 fx. Thus the total dose was 67-70Gy/40-43fx/40-49 d.

Results: The 1-, 3- and 5-year overall survival was 90.9 %, 54.6 %, 47.8 % respectively. The 1-, 3- and 5-year local control rate was 90.9 %, 84.5 % and 84.5 %, respectively. Twenty-five percent (14/56) patients had distant metastasis and/or lymph nodes metastasis alone. Eight point nine percent (5/56) patients had local disease alone. Another 3.6 % (2/56) patients had regional relapse and distant metastasis.

Conclusion: Late course accelerated hyperfractionated radiotherapy is effective on clinical T(1-2) esophageal carcinoma. The main failure pattern is distant metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The overall survival rates for clinical T1-2 esophageal carcinoma treated with LCAF radiotherapy.
Figure 2
Figure 2
The local control rates for clinical T1-2 esophageal carcinoma treated by LCAF radiotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol. 1999;51:21–26. - PubMed
    1. Murakami M, Kuroda Y, Nakajima T, Okamoto Y, Mizowaki T, Kusumi F, Hajiro K, Nishimura S, Matsusue S, Takeda H. Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:277–284. - PubMed
    1. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg. 1999;230:392–400; discussion 400-3. - PMC - PubMed
    1. Vigneswaran WT, Trastek VF, Pairolero PC, Deschamps C, Daly RC, Allen MS. Extended esophagectomy in the management of carcinoma of the upper thoracic esophagus. J Thorac Cardiovasc Surg. 1994;107:901–96; discussion 901-96;. - PubMed
    1. Zenone T, Romestaing P, Lambert R, Gerard JP. Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus. Eur J Cancer. 1992;28A:1380–1386. - PubMed